Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

To evaluate whether pathologic complete response (pCR) to neoadjuvant trastuzumab is dependent on the level of HER2 amplification. 114 HER2-overexpressing early breast cancer patients who had received neoadjuvant trastuzumab were included in this study. Absolute HER2 and chromosome 17 centromere (CE...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-07, Vol.23 (14), p.3676-3683
Hauptverfasser:	Singer, Christian F, Tan, Yen Y, Fitzal, Florian, Steger, Guenther G, Egle, Daniel, Reiner, Angelika, Rudas, Margaretha, Moinfar, Farid, Gruber, Christine, Petru, Edgar, Bartsch, Rupert, Tendl, Kristina A, Fuchs, David, Seifert, Michael, Exner, Ruth, Balic, Marija, Bago-Horvath, Zsuzsanna, Filipits, Martin, Gnant, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Amplification Biomarkers Biomarkers, Pharmacological Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Centromere - genetics Chromosome 17 Chromosomes, Human, Pair 17 - genetics Confidence intervals Disease-Free Survival ErbB-2 protein Experimental design Female Humans Hybridization analysis Immunotherapy In Situ Hybridization, Fluorescence Levels Middle Aged Monoclonal antibodies Neoadjuvant Therapy - adverse effects Patients Receptor, ErbB-2 - genetics Regression analysis Statistical analysis Targeted cancer therapy Trastuzumab Trastuzumab - administration & dosage Trastuzumab - adverse effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!